MCM
PTGX icon

MAI Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

MAI Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14
Closed -$1.48K – 4062
2026
Q1 		$1.48K Sell
14
-83
-86% -$7.35K ﹤0.01% 4040
2025
Q4 		$8.47K Buy
97
+11
+13% +$900 ﹤0.01% 2917
2025
Q3 		$5.71K Hold
86
– – ﹤0.01% 2972
2025
Q2 		$4.75K Buy
+86
New +$4.13K ﹤0.01% 3068

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

MAI Capital Management's PTGX Position: Q2 2026 in Review

MAI Capital Management sold out of Protagonist Therapeutics (PTGX) in Q2 2026, closing a stake of 14 shares — an estimated $1.48K sold.

MAI Capital Management first reported a position in PTGX in Q2 2025 and held it in 4 quarters. The position peaked at $8.47K in Q4 2025. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • MAI Capital Management reported no remaining Protagonist Therapeutics position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 14 Protagonist Therapeutics shares in Q2 2026, an estimated $1.48K.
  • MAI Capital Management first reported a position in Protagonist Therapeutics in Q2 2025 and held it in 4 quarters.
  • MAI Capital Management's Protagonist Therapeutics position peaked at $8.47K in Q4 2025.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.